Please assess the completion status of the following clinical trial:

Trial Title: Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give informed consent~* Presence of an ileostomy \> 2 months~* Weight stable\* for \>2 months (i.e. no greater than 7% change in body weight the last 2 months)~Exclusion Criteria:~* Crohn's Disease~* Steroid use in the last 3 months~* Documented/known diagnosis of type 1 diabetes or type 2 diabetes, chronic liver disease, chronic kidney disease, heart failure, cardiac dysrhythmias, or familial hypercholesterolemia~* Current use of any over-the-counter or prescription oral bile salt~* Currently pregnant~* Current use of medications that are known to interact with Ursodiol~* Current or former smoker within the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ursodeoxycholic Acid/Placebos (Type: ACTIVE_COMPARATOR): During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
- Placebos/Ursodeoxycholic Acid (Type: ACTIVE_COMPARATOR): Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).